TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Endo Pharmaceuticals Solutions Inc.		11/30/2010	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	JPMorgan Chase Bank, N.A., as Administrative Agent
Street Address:	10 South Dearborn
City:	Chicago
State/Country:	ILLINOIS
Postal Code:	60603
Entity Type:	National Banking Assocation: UNITED STATES

PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
Registration Number:	0589157	DELATESTRYL
Registration Number:	2337316	HYDRON
Registration Number:	2547623	HYDRON
Registration Number:	3040977	I INDEVUS PHARMACEUTICALS, INC.
Registration Number:	3007230	INDEVUS PHARMACEUTICALS
Registration Number:	2875279	INDEVUS PHARMACEUTICALS
Registration Number:	1638851	SUPPRELIN
Serial Number:	77332945	VALSTAR
Registration Number:	2929415	VANTAS

CORRESPONDENCE DATA

Fax Number: (214)981-3400

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 214-981-3483
Email: dclark@sidley.com

TRADEMARK
REEL: 004423 FRAME: 0338

900177655

Correspondent Name: Dusan Clark, Esq. Address Line 1: Sidley Austin LLP Address Line 2: 717 N. Harwood St., Suite 3400 Dallas, TEXAS 75201 Address Line 4: ATTORNEY DOCKET NUMBER: 36084-36730 NAME OF SUBMITTER: Dusan Clark /Dusan Clark/ Signature: 12/01/2010 Date: **Total Attachments: 5** source=EPS CGSI TM#page1.tif source=EPS CGSI TM#page2.tif source=EPS CGSI TM#page3.tif source=EPS CGSI TM#page4.tif source=EPS CGSI TM#page5.tif

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "<u>Confirmatory Grant</u>") is made effective as of November 30, 2010 by and from ENDO PHARMACEUTICALS SOLUTIONS INC., a Delaware corporation (the "<u>Grantor</u>"), to and in favor of JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the "<u>Grantee</u>").

WHEREAS, Endo Pharmaceuticals Holdings Inc. (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Grantor, along with certain other Subsidiaries of the Borrower, has guaranteed the repayment of the Secured Obligations pursuant to a Guaranty dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty").

WHEREAS, the Borrower, the Grantor and certain Subsidiaries of the Borrower have entered into a Pledge and Security Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor owns the trademarks listed on <u>Exhibit A</u> attached hereto (the "<u>Trademarks</u>"), which Trademarks are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) <u>Definitions</u>. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement.

2) <u>The Security Interest.</u>

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of (i) all the Secured Obligations and (ii) all of the obligations and liabilities of the Subsidiary Guarantors under the Guaranty. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Trademarks acquired under the Security Agreement and this Confirmatory Grant.

- (b) The Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in (1) all of the Grantor's right, title and interest in and to its trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the Trademarks, now owned or from time to time after the date hereof owned or acquired by the Grantor and the goodwill of the business symbolized by the foregoing; (2) all licenses of the foregoing, whether as licensee or licensor; (3) all renewals of the foregoing; (4) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; and (5) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing.
- 3) Governing Law. THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.

ENDO PHARMACEUTICALS SOLUTIONS INC.

Vame: Alan G. Levin

Title: Executive Vice President and Chief Financial

Officer

Signature Page for Grant of Security Interest in United States Trademarks

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS Exhibit A - SCHEDULE OF TRADEMARKS

Exhibit A

Endo Pharmaceuticals Solutions Inc.

Trademark	Country	App. No.	App.Date	Reg. No.	Reg.Date Owner	Owner
AVEED	United States	77/736,575	5/14/2009			Endo Pharmaceuticals Solutions Inc.
DELATESTRYL	United States	71/649,803	7/3/1953	0,589,157	4/27/1954	Endo Pharmaceuticals Solutions Inc.
HYDRON	United States	75/482,236	5/8/1998	2,337,316	4/4/2000	Endo Pharmaceuticals Solutions Inc.
HYDRON	United States	75/481,957	5/8/1998	2,547,623	3/12/2002	Endo Pharmaceuticals Solutions Inc.
I INDEVUS	United States	78/511,215	11/4/2004	3,040,977	1/10/2006	Endo Pharmaceuticals Solutions Inc.*
PHARMACEUTICALS &						
Design						
INDEVUS	United States	78/285,011	8/8/2003	3,007,230	10/18/2005	18/2005 Endo Pharmaceuticals Solutions Inc.*
PHARMACEUTICALS						
INDEVUS	United States	76/355,179	1/4/2002	2,875,279	8/17/2004	Endo Pharmaceuticals Solutions Inc.*
PHARMACEUTICALS						
SUPPRELIN	United States	74/004,595	11/22/1989	1,638,851	3/26/1991	Endo Pharmaceuticals Solutions Inc.
VALSTAR	United States	77/332,945	11/19/2007			Endo Pharmaceuticals Solutions Inc.
VANTAS	United States	76/522,929	6/17/2003	2,929,415	3/1/2005	Endo Pharmaceuticals Solutions Inc.

^{*} Currently in the name of Indevus Pharmaceuticals, Inc. Recordation of Name Change to Endo Pharmaceuticals Solutions Inc. is in process.

RECORDED: 12/01/2010